Hematology and Oncology

01Purpose and scope

• This manual supports the course Hematology and Oncology. It describes how clinicians, nurses, pharmacists, laboratory staff and care coordinators actually carry out work with patients who have blood disorders, blood cancers and solid tumors that need systemic therapy or supportive care. It is written as a working reference for people who already have some clinical training and need a clear picture of the day-to-day sequence of decisions, handoffs and records.
• The scope covers diagnostic evaluation of cytopenias, anemia, bleeding and clotting problems, and suspected malignancy; treatment planning for leukemias, lymphomas, myeloma and solid tumors; monitoring during and after therapy; and supportive care such as transfusion, growth factor use, infection prevention and symptom management. It does not attempt to teach the full biology of every disease. Readers who need that depth should use current specialty texts and guidelines from recognized professional societies.
• This manual is not a substitute for qualified professional judgment, approved institutional procedures or required authorization. Dosing, eligibility for specific agents, transfusion thresholds and consent requirements vary by patient, by diagnosis, by jurisdiction and by facility policy. Where rules depend on location, check the current requirements from the relevant health authority and your organization's pharmacy and therapeutics committee.

02Core principles

• Hematology and oncology work rests on accurate diagnosis before treatment. A complete blood count, peripheral smear review, chemistry panel and, when indicated, bone marrow aspiration with flow cytometry, cytogenetics or molecular testing together define the disease. Treating a result without the full picture is one of the most common sources of avoidable harm in this field.
• Treatment intent shapes every decision. A curative plan for a patient with early-stage Hodgkin lymphoma carries different toxicity tolerance than a palliative plan for metastatic disease. Before a regimen is selected, the team should agree on what outcome the patient is aiming for, and that goal should be written in the chart in plain language.
• Continuity matters as much as the individual decision. Many patients receive care over months or years across infusion chairs, clinic visits, emergency departments and home care. Every handoff is a chance for a dose, a result or a symptom report to be lost, so the working principle is that every open item has a named owner and a due date.

03Planning and preparation

• Start by confirming the diagnosis and staging with the source documents rather than summaries. Pathology reports, imaging, prior treatment records and laboratory trends should all be reviewed directly. For hematologic malignancies, confirm the subtype, risk classification and any molecular markers that change the therapy choice. For solid tumors, confirm the histology, biomarker status and the date and extent of any prior surgery or radiation.
• Next, assess the patient's baseline function and fitness. Performance status scoring, organ function (renal, hepatic and cardiac), prior toxicities, allergies, infection history, vaccination status and social factors such as transportation and caregiver availability all shape whether a regimen is feasible. Document these before the first dose, because later decisions depend on them.
• Prepare the logistics before the treatment day. This includes confirming the consent discussion and signed consent, ordering pre-treatment labs with appropriate lead time, verifying insurance or prior authorization where required, scheduling chair time and pharmacy compounding, and arranging education on fever precautions and who to call after hours. Many delays in infusion programs come from a missing authorization or a pharmacy order entered without the correct dose weight or creatinine clearance.

04Recommended workflow

1. 1
   : Establish the working diagnosis and treatment intent. Review all pathology, cytogenetic and molecular results, then write a short problem statement that names the disease, its stage or risk group, and the goal of therapy. Share this statement with the multidisciplinary team so that everyone is working from the same assumptions.
2. 2
   : Confirm baseline labs and organ function. Obtain a current complete blood count with differential, comprehensive metabolic panel, coagulation studies where relevant, and any disease-specific markers such as lactate dehydrogenase or serum protein electrophoresis. Calculate renal function using the method your pharmacy uses, since the formula chosen affects dose adjustments for some agents.
3. 3
   : Select the regimen and obtain approvals. The treating physician chooses the regimen, usually based on a recognized guideline pathway or a clinical trial protocol. Pharmacy verifies the order against dose calculation rules, interactions and the patient's allergy and prior toxicity record. Insurance or payer authorization is requested in parallel where it is required.
4. 4
   : Deliver education and obtain consent. Explain the expected benefits, common side effects, serious risks and the monitoring schedule in language the patient can repeat back. Use teach-back to confirm understanding. Record who was present, which materials were given and what questions were answered. Consent should be obtained by a clinician with the authority to do so under local rules.
5. 5
   : Administer and monitor during treatment. Nursing staff verify patient identity, check the order against the labeled product, observe for infusion reactions and document vital signs at the frequency the protocol requires. Hazardous drugs are prepared and given with the containment and personal protective equipment that the facility requires. Pre-medications are given as ordered, and any deviation is reported to the prescriber before the infusion continues.
6. 6
   : Review response, toxicity and next steps. At each visit, compare the current labs and symptoms with the baseline and the prior cycle. Grade adverse events using a recognized scale such as the Common Terminology Criteria for Adverse Events, and decide whether to continue, hold, reduce or change therapy. Update the treatment plan in the chart, then communicate the decision to the patient and the nursing and pharmacy teams before the next cycle begins.

05Quality checks, risk controls and compliance

• Build checks into the process rather than relying on memory. Independent double checks are standard for high-alert medications, including chemotherapy, and many facilities add a second verification of weight, body surface area, and calculated dose before compounding. Barcode scanning at the bedside and pharmacy label reviews catch many errors, but they only work if the order in the system matches the intended treatment.
• Hazardous drug handling is governed by occupational rules and by guidance from agencies such as the National Institute for Occupational Safety and Health, which maintains a list of hazardous drugs that is reviewed periodically. Staff who prepare, administer or clean up after these drugs need training, appropriate gloves and gowns, closed system transfer devices where available, and a spill kit. Waste disposal follows the facility's hazardous waste program and applicable regulations, which differ by state and country.
• Laboratory testing used to guide treatment falls under federal and state rules in the United States, including the Clinical Laboratory Improvement Amendments, which set quality requirements for labs performing patient testing. Bone marrow and molecular assays are often performed in specialized labs with their own validation and proficiency programs. Confirm that any send-out test is performed by a certified laboratory and that the result report includes the methods and reference ranges needed for interpretation. Privacy and records rules, such as the Health Insurance Portability and Accountability Act in the United States, apply to all clinical communications, including messages between team members. Check current local requirements, since the rules vary by jurisdiction.

06Collaboration and documentation

• Hematology and oncology care is delivered by teams. The core roles usually include the treating hematologist or oncologist, an advanced practice provider, oncology nurses, a clinical pharmacist, a laboratory or pathology contact, a social worker or navigator, and palliative care when symptoms or goals call for it. Radiation oncology, transplant teams, infectious disease and surgery join as needed. Each role should be named in the care plan with its responsibilities written out, so that questions about who checks a lab trend or who calls the patient after a fever have a clear answer.
• The treatment plan is the central document. It should state the diagnosis, intent, regimen name and version, dose and dose calculation basis, cycle length, planned monitoring, dose modification rules, and the criteria for stopping therapy. Progress notes should record the response assessment, toxicities with grades, decisions and the reasons for them. Avoid copying forward unchanged text, since stale information is a frequent source of errors during handoffs.
• Communication outside the chart matters too. Tumor boards and multidisciplinary conferences are useful for complex cases, but they only help when the presenter sends the pathology, imaging and treatment history in advance and the decision is recorded afterward. Patient messages about fever, bleeding, new confusion or inability to keep fluids down need a defined triage route with a response time, and the staff member receiving the message should document what they advised and who they escalated to.

07Measures and continuous improvement

• Track indicators that show whether care is safe, timely and consistent with the plan. Useful measures include the proportion of treatment orders verified before the first dose, the rate of unplanned hospital admissions for fever or infection within a defined period after chemotherapy, time from referral to first clinic visit for suspected hematologic malignancy, rates of missed or delayed scheduled labs, and documented completion of consent and education before treatment. Choose a small set that the team can collect consistently, since a long list of metrics that nobody reviews adds work without improving care.
• Use the results in a regular review, such as a monthly quality meeting, to find patterns. A cluster of delayed authorizations might point to a missing step in the intake process. A cluster of febrile neutropenia admissions might suggest that patient education or the triage phone line needs work. Make one change at a time where possible, then check whether the indicator moved as expected before deciding whether to keep it.
• Limits apply to any measure. Small programs have too few patients for meaningful rates, and case mix differences can make two clinics look different when they are not comparable. Published outcome benchmarks depend on the population studied and the definitions used, so compare your figures with others only when the definitions match. Share lessons with colleagues in the same specialty, and consult the current guidance from professional societies when a practice question arises.

08Common mistakes and how to prevent them

• A frequent mistake is dosing from an outdated weight or height. Patients lose or gain weight during treatment, and a dose calculated from the admission weight may be too high or too low by the time of the infusion. Require current weights at each cycle and make the pharmacy verification step check the weight date.
• Another common error is failing to act on a laboratory result that arrives after the clinic visit. Pending or late results from send-out tests, cytogenetics or flow cytometry are often filed without review. Assign an owner for pending results and set a rule that every abnormal result is acknowledged by a clinician within a set time frame.
• Teams also miss delayed toxicity. Neuropathy, mucositis, fatigue, mood changes and cognitive symptoms may appear after the infusion day, and patients often do not mention them unless asked directly. Use a structured symptom review at each visit, and give the patient a written list of symptoms that require a call the same day.

09Practical checklist

• Confirm the diagnosis, subtype or stage, and the treatment intent from source reports before ordering therapy.
• Record baseline labs, organ function, performance status and prior toxicities in the chart before the first dose.
• Verify the regimen, dose calculation, current weight and dose modification rules through an independent check.
• Document consent, education, teach-back and the contact plan for after-hours symptoms.
• Confirm authorization, chair time and pharmacy preparation are complete before the treatment day.
• Review labs and grade toxicities at each visit, and document the decision to continue, hold, reduce or change therapy.
• Assign an owner and a response time to every pending result and every patient message that requires action.
• Update the treatment plan and communicate changes to nursing, pharmacy and the patient before the next cycle.

★Learning sources

• Micro Degree: Hematology and Oncology
• Micro Degree: Healthcare Administration Practice
• Micro Degree: Physiotherapy Assistant Operations
• Micro Degree: Cardiac Care Support